Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Revisiting erythroid response in the phase 3 BELIEVE trial of luspatercept in patients with transfusion-dependent β-thalassemia using real-world criteria

Khaled Musallam, Maria Domenica Cappellini, Antonis Kattamis, Kevin Kuo, Sujit Sheth, Patricia Martin-Regueira, Loyse Felber Medlin, George Zhang, Christopher Westcott, Ali Taher

Blood (2025) 146 (Supplement 1): 1139.

https://doi.org/10.1182/blood-2025-1139

Published: 2025

Journal Articles

Safety data from the non-transfusion-dependent dose-confirmation cohort: A phase 2a study of luspatercept in pediatric patients with β-thalassemia

Vip Viprakasit, Jianpei Fang, Khaled Musallam, Yesim Aydinok, Thomas Coates, Olga Grabowska, Iryna Bluemmert, Wenlei Yu, Patricia Martin-Regueira, Nour Hawila, Giovanni Battista Ferrero

Blood (2025) 146 (Supplement 1): 1135.

https://doi.org/10.1182/blood-2025-1135

Published: 2025

Journal Articles

Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent β-thalassemia: Results from the phase 3b long-term follow-up study

Ali Taher, Khaled Musallam, Maria Domenica Cappellini, Maria Dimopoulou, Antonis Kattamis, Silverio Perrotta, Paolo Ricchi, Manuela Balocco, Patricia Martin-Regueira, Loyse Felber Medlin, George Zhang, Veronika Pozharskaya, John Porter

Blood (2025) 146 (Supplement 1): 4695.

https://doi.org/10.1182/blood-2025-4695

Published: 2025

Journal Articles

A phase 2 study of luspatercept in adults and adolescents with α-thalassemia: Findings from the dose-confirmation cohort in adolescents

Yongrong Lai, Meng-Yao Lu, Ying Zhao, Antonis Kattamis, Gian Luca Forni, Kitty Formentin, Pablo Gurman, Mingzhao Gao, Loyse Felber Medlin, Patricia Martin-Regueira, Vincent Jaquet, Vip Viprakasit

Blood (2025) 146 (Supplement 1): 4689.

https://doi.org/10.1182/blood-2025-4689

Published: 2025

Journal Articles

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Blood (2025) 146 (Supplement 1): 907.

https://doi.org/10.1182/blood-2025-907

Published: 2025

Journal Articles

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Blood (2023) 141 (2): 156–167.

https://doi.org/10.1182/blood.2021014901

Published: 2023

Includes: Supplemental data

Journal Articles

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi

Blood (2022) 140 (Supplement 1): 3865–3867.

https://doi.org/10.1182/blood-2022-166407

Published: 2022

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 9647–9649.

https://doi.org/10.1182/blood-2022-164444

Published: 2022

Journal Articles

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

Blood (2022) 140 (Supplement 1): 3935–3937.

https://doi.org/10.1182/blood-2022-156669

Published: 2022

Journal Articles

Outcomes for Patients with Late-Stage Mutant- IDH2 (m IDH2 ) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

Courtney D. DiNardo, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Amer M. Zeidan, Iryna Bluemmert, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Stephane de Botton

Blood (2021) 138 (Supplement 1): 1243.

https://doi.org/10.1182/blood-2021-147593

Published: 2021

Journal Articles

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Courtney D. DiNardo, Hartmut Dohner, Amer M. Zeidan, Andre C. Schuh, Paresh Vyas, Eytan M. Stein, Andrew H. Wei, Stephane de Botton, Clara Chen, Jennifer Lord-Bessen, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Shien Guo, Ling Shi, Pau Montesinos

Blood (2021) 138 (Supplement 1): 1244.

https://doi.org/10.1182/blood-2021-147601

Published: 2021

Journal Articles

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

Courtney D. DiNardo, Gautam Borthakur, Brian Ball, Harry P. Erba, Raya Mawad, Marina Kremyanskaya, James S. Blachly, Hetty E. Carraway, Ahrim Youn, Jessica Garzon, Daniel Lopes de Menezes, Patricia Martin-Regueira, C.L. Beach, Justin Watts

Blood (2021) 138 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2021-146791

Published: 2021

Journal Articles

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell

Blood (2021) 137 (5): 637–645.

https://doi.org/10.1182/blood.2019004753

Published: 2021

Includes: Supplemental data

Journal Articles

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Jorge E. Cortes, MD, Qian Jiang, MD, Jianxiang Wang, MD, Jianyu Weng, MD, Huanling Zhu, MD, Liu Xiaoli, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Jerald Radich, MD, Michael R. Savona, MD, Patricia Martin Regueira, MD, Oumar Sy, PhD, Renuka Gurnani, BA, Giuseppe Saglio

Blood (2018) 132 (Supplement 1): 788.

https://doi.org/10.1182/blood-2018-99-111978

Published: 2018

Journal Articles

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, MD PhD, Antonio Jiménez-Velasco, MD, Sarah Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Yair Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin Regueira, MD, Jeffrey H. Lipton, MD PhD

Blood (2018) 132 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2018-99-116563

Published: 2018

Journal Articles

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, PhD, Antonio Jiménez-Velasco, MD, Sarah M Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin-Regueira, MD, Jeffrey H. Lipton, PhD MD FRCPC

Blood (2017) 130 (Supplement 1): 314.

https://doi.org/10.1182/blood.V130.Suppl_1.314.314

Published: 2017

Journal Articles

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Neil P. Shah, MD PhD, Ronald Paquette, MD, Martin C. Müller, MD, Susanne Saussele, MD, Valentin Garcìa-Gutiérrez, MD, Antonio Jiménez-Velasco, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Francois-Xavier Mahon, MD PhD, Delphine Rea, MD PhD, Patricia Martin-Regueira, MD, Milayna Subar, MD, Li Li, PhD, Jeffrey H. Lipton, MD PhD

Blood (2016) 128 (22): 1895.

https://doi.org/10.1182/blood.V128.22.1895.1895

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Revisiting erythroid response in the phase 3 BELIEVE trial of luspatercept in patients with transfusion-dependent β-thalassemia using real-world criteria

Safety data from the non-transfusion-dependent dose-confirmation cohort: A phase 2a study of luspatercept in pediatric patients with β-thalassemia

Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent β-thalassemia: Results from the phase 3b long-term follow-up study

A phase 2 study of luspatercept in adults and adolescents with α-thalassemia: Findings from the dose-confirmation cohort in adolescents

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Outcomes for Patients with Late-Stage Mutant- IDH2 (m IDH2 ) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only